Reaction
Hepatobiliary Disease reporting signals
As of the last recalculation, Hepatobiliary Disease appears in 622 FAERS reports alongside 28 co-occurring drug terms. The strongest observed disproportionality signal is ERLOTINIB (PRR 42.2).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Erlotinib | 12 | 42.2 | 42.3 |
| Ritonavir 100 Mg | 18 | 41.5 | 41.5 |
| Gefitinib | 10 | 37.7 | 37.7 |
| Mesna Injection | 8 | 32.8 | 32.8 |
| Erlotinib Hydrochloride | 12 | 32.7 | 32.7 |
| Mesna | 8 | 32.2 | 32.2 |
| Clobazam | 20 | 28.3 | 28.3 |
| Pegaspargase | 9 | 24.9 | 25.0 |
| Ritonavir | 20 | 23.6 | 23.6 |
| Atezolizumab | 26 | 23.3 | 23.4 |
| Sorafenib | 14 | 23.1 | 23.1 |
| Nevirapine | 6 | 22.5 | 22.5 |
| Oxazepam | 14 | 22.3 | 22.3 |
| Tramadol Hydrochloride | 24 | 22.2 | 22.2 |
| Ribociclib | 19 | 20.7 | 20.8 |
| Pazopanib Hydrochloride | 16 | 20.3 | 20.3 |
| Blinatumomab | 6 | 19.4 | 19.4 |
| Busulfan | 9 | 19.4 | 19.4 |
| Granisetron Hydrochloride | 6 | 19.4 | 19.4 |
| Granisetron | 6 | 19.3 | 19.3 |
| Efavirenz | 6 | 18.2 | 18.2 |
| Imatinib | 9 | 17.3 | 17.3 |
| Axitinib | 9 | 15.7 | 15.7 |
| Sofosbuvir | 7 | 12.0 | 12.0 |
| Ipilimumab | 15 | 11.9 | 11.9 |
| Durvalumab | 7 | 11.6 | 11.6 |
| Nivolumab | 32 | 11.6 | 11.6 |
| Polatuzumab Vedotin | 3 | 10.3 | 10.3 |